Edwards Lifesciences Corp (NYSE:EW) VP Donald E. Bobo, Jr. sold 5,500 shares of the company’s stock in a transaction dated Wednesday, October 10th. The stock was sold at an average price of $147.50, for a total transaction of $811,250.00. Following the completion of the transaction, the vice president now owns 25,490 shares in the company, valued at approximately $3,759,775. The sale was disclosed in a legal filing with the SEC, which is available through this link.
EW opened at $143.39 on Friday. The company has a current ratio of 1.86, a quick ratio of 1.47 and a debt-to-equity ratio of 0.19. The stock has a market cap of $36.45 billion, a price-to-earnings ratio of 37.73, a P/E/G ratio of 2.41 and a beta of 0.56. Edwards Lifesciences Corp has a 52-week low of $100.20 and a 52-week high of $175.00.
Edwards Lifesciences (NYSE:EW) last posted its earnings results on Thursday, July 26th. The medical research company reported $1.24 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $1.13 by $0.11. The business had revenue of $972.00 million for the quarter, compared to analysts’ expectations of $968.32 million. Edwards Lifesciences had a net margin of 19.59% and a return on equity of 29.11%. The business’s revenue for the quarter was up 10.0% compared to the same quarter last year. During the same quarter in the prior year, the business earned $1.08 EPS. As a group, analysts expect that Edwards Lifesciences Corp will post 4.67 EPS for the current year.
A number of brokerages recently issued reports on EW. Zacks Investment Research upgraded shares of Edwards Lifesciences from a “hold” rating to a “buy” rating and set a $165.00 price target on the stock in a research note on Saturday, July 14th. Morgan Stanley upped their price target on shares of Edwards Lifesciences from $150.00 to $157.00 and gave the stock an “overweight” rating in a research note on Thursday. BMO Capital Markets upped their price target on shares of Edwards Lifesciences to $162.00 and gave the stock an “outperform” rating in a research note on Tuesday, July 10th. SunTrust Banks dropped their price target on shares of Edwards Lifesciences to $170.00 and set a “buy” rating on the stock in a research note on Friday, August 10th. Finally, Sanford C. Bernstein began coverage on shares of Edwards Lifesciences in a research note on Wednesday, June 27th. They issued a “market perform” rating and a $165.00 price target on the stock. One equities research analyst has rated the stock with a sell rating, six have issued a hold rating and fifteen have issued a buy rating to the company’s stock. Edwards Lifesciences presently has an average rating of “Buy” and a consensus target price of $155.30.
About Edwards Lifesciences
Edwards Lifesciences Corporation provides products and technologies to treat structural heart disease and critically ill patients in the United States and internationally. It offers transcatheter heart valve therapy products comprising transcatheter aortic heart valves and related delivery systems for the nonsurgical replacement of heart valves.
Featured Story: What is a conference call?
Receive News & Ratings for Edwards Lifesciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edwards Lifesciences and related companies with MarketBeat.com's FREE daily email newsletter.